Second, Lenvatinib, a multi-targeted tyrosine kinase inhibitor (TKI), obstructs VEGF receptors (VEGFR1-3), FGFR, and PDGFRα, leading to hypertension (35% compared to 18% in dual therapy), proteinuria, and hepatic dysfunction via vascular destabilization and metabolic dysregulation (62). The gene discussed is FLT1; the disease is hypertensive disorder.